Cohance Lifesciences Limited (BOM:543064)

Cohance Lifesciences Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	162,610	115,325	293,004	172,366	120,256	157,436
Market Cap Growth	-57.38%	-60.64%	69.99%	43.33%	-23.61%	24.49%
Enterprise Value	164,581	117,196	287,341	165,176	117,048	156,449
Last Close Price	425.05	301.90	1159.80	676.60	472.70	608.03

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	90.73	64.35	60.12	57.40	29.24	34.69
PS Ratio	7.17	5.08	11.23	16.40	8.97	11.93
PB Ratio	4.03	2.86	7.73	8.40	6.93	10.31
P/TBV Ratio	6.43	4.56	12.72	8.67	7.19	10.32
P/FCF Ratio	109.55	77.69	82.18	51.78	70.21	61.79
P/OCF Ratio	44.15	31.31	43.51	44.80	26.30	47.71

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	7.25	5.17	11.02	15.71	8.73	11.85
EV/EBITDA Ratio	38.54	27.45	36.05	40.39	20.44	27.00
EV/EBIT Ratio	68.67	48.90	45.59	46.61	22.25	28.89
EV/FCF Ratio	110.87	78.95	80.59	49.62	68.34	61.40

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.10	0.10	0.13	0.03	0.04	0.06
Debt / EBITDA Ratio	0.94	0.94	0.61	0.16	0.12	0.17
Debt / FCF Ratio	2.70	2.70	1.36	0.20	0.41	0.38
Net Debt / Equity Ratio	0.02	0.02	0.05	-0.37	-0.24	-0.28
Net Debt / EBITDA Ratio	0.18	0.18	0.24	-1.85	-0.72	-0.74
Net Debt / FCF Ratio	0.50	0.50	0.54	-2.27	-2.41	-1.68
Asset Turnover	0.41	0.41	0.67	0.50	0.71	0.80
Inventory Turnover	1.29	1.29	2.33	1.32	1.87	2.24
Quick Ratio	1.56	1.56	1.53	8.61	4.17	3.85
Current Ratio	2.83	2.83	2.54	10.68	6.37	5.36
Return on Equity (ROE)	3.84%	3.84%	16.57%	15.86%	25.21%	33.52%
Return on Assets (ROA)	2.67%	2.67%	10.18%	10.50%	17.33%	20.49%
Return on Invested Capital (ROIC)	4.30%	4.29%	17.99%	20.05%	31.95%	32.95%
Return on Capital Employed (ROCE)	4.70%	4.70%	13.20%	16.60%	29.10%	33.40%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	1.10%	1.55%	1.66%	1.74%	3.42%	2.88%
FCF Yield	0.91%	1.29%	1.22%	1.93%	1.42%	1.62%
Dividend Yield	-	-	-	-	0.64%	0.33%
Payout Ratio	-	-	-	-	49.52%	22.44%
Buyback Yield / Dilution	0.36%	0.36%	-50.98%	-	0.00%	0.00%
Total Shareholder Return	0.36%	0.36%	-50.98%	-	0.64%	0.33%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error